In 2018, after launching Bonjesta® (doxylamine succinate and pyridoxine hydrochloride), Duchesnay USA utilized a combination of retail and specialty pharmacies to support patient access to the medication. This channel strategy experienced challenges, particularly around patient experience and prescription coverage rates.
In 2022, the Duchesnay team engaged Phil Inc looking for ways to address their patient experience and access challenges:
Shipping time: Patients experienced delays to therapy after paying their out of pocket expenses.
Low insurance utilization: only 5-10% of scripts were being covered by insurance
Billing issues: inaccurate billing resulted in overcharges and double billing
After an extensive search, Duchesnay USA decided to partner with Phil Inc and launched in January, 2023. Following launch, patients were seamlessly transferred from their prior specialty pharmacy to the PhilRx Patient Access Platform where they saw marked improvements in patient access and experience in just a few months.
Insurance Coverage: 4x increase in the percentage of dispenses covered by payers
Speed to Therapy: scripts shipping in less than 1 day making it easier to get started on therapy
On the back of the Bonjesta® program success, Duchesnay USA is adding an additional therapy onto the PhilRx Platform, Osphena® (ospemifene). Osphena® is a prescription oral pill that treats moderate to severe painful intercourse and/or moderate to severe vaginal dryness, both symptoms of changes in the vagina due to menopause. Osphena® has a BOXED WARNING regarding Endometrial Cancer and Cardiovascular Disorders. Please keep reading below for Important Safety Information.
By adding Osphena® to the PhilRx platform, Duchesnay USA seeks to improve patient access and adherence to the medication while improving the patient experience, and increasing the percentage of prescriptions covered by insurance.
Indication: What is Osphena®?
Osphena is a prescription oral pill that treats moderate to severe painful intercourse and/or moderate to severe vaginal dryness, both symptoms of changes in your vagina, due to menopause.
Most Important Information you should know about Osphena®
WARNING: ENDOMETRIAL CANCER AND CARDIOVASCULAR DISORDERS Osphena® works like estrogen in the lining of the uterus (endometrium), but can work differently in other parts of the body. Taking estrogen alone or Osphena® may increase your chance for getting cancer of the lining of the uterus. Vaginal bleeding after menopause may be a warning sign of cancer of the lining of the uterus. Your healthcare provider should check any unusual vaginal bleeding to find out the cause, so tell him or her right away if this happens while you are using Osphena®. Osphena® may increase your chances of having a stroke or blood clots. You and your healthcare provider should talk regularly about whether you still need treatment with Osphena®.
Call your healthcare provider right away if you have unusual vaginal bleeding, changes in vision or speech, sudden new severe headaches, and pains in your chest or legs with or without shortness of breath, weakness and fatigue.
Who should not take OSPHENA?
Osphena® should not be used if you have unusual vaginal bleeding, have had certain types of cancers, have or have had blood clots, had a stroke or heart attack, have severe liver problems, are allergic to Osphena® or any of its ingredients, or think you may be pregnant. Tell your healthcare provider if you are going to have surgery or will be on bed rest.
POSSIBLE SIDE EFFECTS Serious but less common side effects can include: stroke, blood clots and cancer of the lining of the uterus.
Less serious, but common side effects include: hot flushes or flashes, vaginal discharge, muscle spasms, headache, excessive sweating (hyperhidrosis), heavy vaginal bleeding (vaginal hemorrhage), night sweats
Tell your healthcare provider about all of the medicines and supplements you take, as some medicines may affect how Osphena® works. Osphena® may also affect how other medicines work.
Duchesnay USA encourages you to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Please read accompanying Patient Information for Osphena®(ospemifene) tablets, including Boxed Warning in the U.S. Full Prescribing Information.
Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance.